Lupus

Comparing EULAR (2025) and ACR (2020) Guidelines on Safety of Lupus Medications in Pregnancy Attendees at the 2025 RheumaPreg meeting were excited to discuss the newly released EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation. https://t.co/DSYPaElRij
Dr. John Cush @RheumNow( View Tweet )
Retrospective cohort study 112 biopsy-proven Lupus nephritis pts (65% class IV; F/U 8.3 yrs). (64.3%), alone or in combination. Renal damage incr betw 5 & 10 yrs F/U. 13.4% progressed to renal function impairment, and 11.6% to ESRD. Early Dx & Rx of LN, esp w/ highproteinuria, https://t.co/yHzN1Hczb4
Dr. John Cush @RheumNow( View Tweet )
QOL survey of on 5222 lupus pts (94% F; 56% both CLE/SLE; 40% w/ SLE. QOL concerns on social activities (60%), mental health (38%). CLE had increased therapeutic hesitancy and less likely to believe in the efficacy of biologics than SLE or both. https://t.co/BOUXUSmmcM https://t.co/zrzEsDDqVn

Links:

Dr. John Cush @RheumNow( View Tweet )
heart2.ekg_.red_.jpg

Assessing and Treating CV Risk Increases in Systemic Lupus

Maureen A. McMahon, MD

We’ve recognized the increased risk of cardiovascular disease (CVD) in SLE for almost half a century since Urowitz et al. first described a bimodal pattern of mortality in lupus patients in 1976. Numerous subsequent studies have confirmed this, with estimates of increased risk ranging from 2-10-

Read Article
light-bulbs-1125016_640.jpg

Lupus in an empty house

Eric Dein, MD

The full house immunofluorescence pattern is the classic histopathologic finding of lupus and lupus nephritis. Glomerular deposits staining for IgG, IgA, IgM, C3 and C1q can help confirm a suspected diagnosis of SLE. But what about patients with negative immunofluorescence and no proliferative

Read Article
Full read overview of Discoid Lupus. https://t.co/G6lXWTRSFn https://t.co/yjVsDg0D5d

Links:

Dr. John Cush @RheumNow( View Tweet )
Betw 2005 -2021, there was a substantial increase in HCQ use, but only modest steroid (GC) reductions. Swedish cohort study of 3891 SLE pts - over 5 yrs GC decr from 68% - 54% to 46%. HCQ increased by 29% over 5 years. https://t.co/6LZVMt9zy7 https://t.co/WunjnBBTW9

Links:

Dr. John Cush @RheumNow( View Tweet )
Telitacicept, recombinant fusion protein targeting BLyS & APRIL, studied in 41 Chinese SLE pts (added to standard Rx) showed mean improvements in SLEDAI-2K (10.0 to 6.25 @12 wks & 4.2 @24 wks;p<.001), daily prednisone (21 mg to 9.8mg) & proteinuria (2.8 gr to 1.3 gr/day) https://t.co/xtPMSZBoWg
Dr. John Cush @RheumNow( View Tweet )
Vitamin D Headlines (5.9.2025) Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy. https://t.co/i9OJrYR59T https://t.co/PQ3fAR5teR

Links:

Dr. John Cush @RheumNow( View Tweet )
Telemedicine and Lupus https://t.co/RgfgnMGsZw https://t.co/uQEYLlrlB5

Links:

Dr. John Cush @RheumNow( View Tweet )
TONIGHT! Tuesday Night Rheumatology: 🔓 Lupus Unlocked: Cutaneous SLE Join us for a discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE. Featuring: Dr. Victoria P. Werth Dr. Matilda Nicholas Dr. Anthony Fernandez Dr. Christopher https://t.co/l0QjM9obk2
Dr. John Cush @RheumNow( View Tweet )
Managing CKD in Lupus Nephritis Dr. Hans-Joachim Anders explores how to treat LN patients with chronic kidney disease, balancing disease control and renal preservation. 🎯 Don’t miss these expert pearls. 👉 Full update on RheumNow: https://t.co/frHvcd1xMw #LupusNephritis https://t.co/VedtGaHkMj

Links:

Dr. John Cush @RheumNow( View Tweet )
lupus SLE

Deep remission in SLE – what is it, and can we achieve it?

Ronald van Vollenhoven, MD, PhD

Recent reports on small numbers of lupus patients treated with CAR-T cells directed against CD19+ B lymphocytes have generated considerable excitement, not so much because the initial response to this therapy was favorable, but because after follow-up durations of two years or longer the

Read Article
Full read overview of Discoid Lupus. https://t.co/aXgveR2NwF https://t.co/9JK6CNqedO

Links:

Dr. John Cush @RheumNow( View Tweet )
Lupus Unlocked: Journal Club In this first webinar of RheumNow's Lupus Unlocked campaign, Journal Club discussed two articles: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Furie R, et al. NEJM. 2025 Feb 7. doi: 10.1056 Efficacy and safety of voclosporin https://t.co/OYv5J8VpRB
Dr. John Cush @RheumNow( View Tweet )
Pope

Lessons Learned from a Lupus Registry: Two sides of one coin?

Janet Pope, MD, MPH, FRCPC

I want to talk about a large Canadian registry that sometimes doesn't get as much airtime. Our group is called CaNIOS: Canadian Network for Improved Outcomes in SLE. We've enrolled more than a thousand patients, seen at least annually and some for many years. These patients are incident or

Read Article
Betw 2005 -2021, there was a substantial increase in HCQ use, but only modest steroid (GC) reductions. Swedish cohort study of 3891 SLE pts - over 5 yrs GC decr from 68% - 54% to 46%. HCQ increased by 29% over 5 years. https://t.co/sI7JWq3AGk https://t.co/RBUMcl8uGz

Links:

Dr. John Cush @RheumNow( View Tweet )
Emulation trials in SLE: Real or Fake? Recently a landmark paper was published in A&R studying the results of an emulation trial. My colleagues and I were able to write an editorial on this paper and describe emulation trials. https://t.co/0ulYG5xz0J https://t.co/8oj8UDV9Dd

Links:

Dr. John Cush @RheumNow( View Tweet )
New Steroid Rules in Lupus? Let’s Talk. Dr. Michelle Petri breaks down the latest strategies to minimize steroid exposure while managing disease activity in lupus patients. 💡 Smarter steroid use = better outcomes. 👉 Watch now on RheumNow: https://t.co/vbjrXAlixz #Lupus https://t.co/04CjTkCqMJ

Links:

Dr. John Cush @RheumNow( View Tweet )
Telitacicept, recombinant fusion protein targeting BLyS & APRIL, studied in 41 Chinese SLE pts (added to standard Rx) showed mean improvements in SLEDAI-2K (10.0 to 6.25 @12 wks & 4.2 @24 wks;p<.001), daily prednisone (21 mg to 9.8mg) & proteinuria (2.8 gr to 1.3 gr/day) https://t.co/KHMWPeq79x
Dr. John Cush @RheumNow( View Tweet )
woman-1284353_640.jpg

Comparing EULAR (2025) and ACR (2020) Guidelines on Safety of Lupus Medications in Pregnancy

Catherine Sims, MD

Attendees at the 2025 RheumaPreg meeting were excited to discuss the newly released EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation. Table 1 summarizes the major recommendations from EULAR (2025) and the American College of Rheumatology (2020)

Read Article
Tuesday Night Rheumatology: 🔓 Lupus Unlocked: Cutaneous SLE Join us for a discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE. Featuring: Dr. Victoria P. Werth Dr. Matilda Nicholas Dr. Anthony Fernandez Dr. Christopher Richardson https://t.co/UNazbo9TuZ
Dr. John Cush @RheumNow( View Tweet )
Retrospective study of 131 childhoold SLE pts found lymphopenia (in 53%) significantly correlated w/ higher anti-dsDNA and increased disease activity. (r = −0.63). Lymphopenia assoc w/ more nephritis (72%), HTN (24%), leukopenia (36%) & neuropsychiatric SLE https://t.co/ONUm84jThE
Dr. John Cush @RheumNow( View Tweet )
More Women with Autoimmune Diseases Die from Cardiovascular Disease Women with the autoimmune diseases rheumatoid arthritis, lupus or systemic sclerosis may have a higher rate of death related to cardiovascular disease than men with the autoimmune diseases, according to new https://t.co/Px9ayANsFL
Dr. John Cush @RheumNow( View Tweet )
Certolizumab effective in preventing adverse pregnancy outcomes in high-risk antiphospholipid syndrome. CZP given to 51 APS pts wks 8 to 28. 9 w/ primary APO (17.6%) (6 w/ pregnancy loss <10 wks) - significantly lower than historical controls. Median delivery 36.5 wks. Neonatal https://t.co/KfOOM7sEAt
Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

From DNA to PGA

David Pisetsky, MD, PhD
dna
I have been investigating the mechanisms of antinuclear antibody (ANA) expression in SLE since 1978. In this pursuit, I have followed the advice of my first division chief, Dr. Ralph Snyderman, a great academician.  Ralph told me to identify a research focus and make it mine. I think I have done reasonably well in my mission so you can imagine my surprise (and excitement) when, for the Lupus 2025 meeting in Toronto, I was asked to conduct a Meet the Professor session on the Type 1 & 2 model for SLE. Read Post

Focus on the Fasting Lipid Profile

Dr Paul Anthony John Russo
Blood labs
How best do we communicate CV risk associated with RA to other members of the treating team, most particularly the primary care physicians? After some experimentation, I have come up with an approach that seems to work and which does not take up much time. Read Post
×